BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-652@pharmaconomics
DTSTAMP:20260707T033823Z
DTSTART;VALUE=DATE:20260325
DTEND;VALUE=DATE:20260326
SUMMARY:DNLI Approval — AVLAYAH (tividenofusp alfa-eknm)
DESCRIPTION:A final FDA approval decision on AVLAYAH (tividenofusp alfa-eknm) for Hunter Syndrome (MPS II) is expected Mar 25\, 2026.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1714899/000171489926000030/ex9912026pressrelease32526.htm\n\nTrack it: https://pharmaconomics.com/e/652
URL:https://pharmaconomics.com/e/652
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:DNLI catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR